Treatment of Oral Leukoplakia

Primary Treatment Recommendation

Photodynamic therapy (ALA-PDT) is recommended as the preferred treatment for oral leukoplakia, particularly for extensive lesions or those located in areas with underlying functional structures, due to its minimally invasive nature, efficacy, and low risk of systemic side effects and disfigurement 1, 2, 3

The American College of Oral Medicine recommends preparation and application of aminolevulinic acid (ALA) to yield a 20% aqueous solution immediately before use, and apply the photosensitizer to the lesion surface after local anesthesia with 2% lidocaine or 4% primacaine 2
The treatment parameters for ALA-PDT include using a semiconductor laser light source at 630 nm ± 5 nm, power setting of 100 mW/cm², and irradiation protocol of 3-minute sessions followed by 3-minute rest periods to maintain effective intracellular oxygen concentrations 2
The total light exposure dose for ALA-PDT is 100 J/cm², and the treatment frequency is once every 2-3 weeks depending on lesion healing 2, 3
Response rates for ALA-PDT range from 50% to 100%, with complete response rates of 16.49% to 88.89%, and recurrence rates range from 0% to 41% over 1-30 months of follow-up 2

The American Dental Association recommends prescribing topical 0.01% dexamethasone paste and 0.1% chlorhexidine gargling solution to reduce inflammation, and instructing patients to keep mouth clean and avoid irritating foods and drinks 2, 3
Preventing light exposure to treated area for at least 48 hours is critical, and extending throughout entire treatment course for exposed sites like lips 2, 3

The evaluation timeline for treatment response is 4 weeks after the last treatment, and response criteria include complete response (CR), partial response (PR), and no response (NR) 2

Non-homogeneous leukoplakia has significantly higher malignant transformation risk than homogeneous type, and requires aggressive management 4, 5
Failing to protect treated areas from light exposure for full 48 hours minimum is a common error, and using chemoprevention with expectation of preventing malignant transformation is not supported by evidence 2, 3, 4

The International Journal of Oral Science guidelines state that absolute contraindications for ALA-PDT include a history of porphyria, coagulopathy, pregnancy, uncontrolled severe systemic disorders, and allergy to light, porphyrin, or anesthesia agents 6